Blog
Blog
Health Care and Life Science at HBS
Health Care and Life Science at HBS
Health Care Initiative (HCI) is excited to welcome Professor Leemore Dafny as our new Howard Cox Faculty Co-Chair. Dafny, the Bruce V. Rauner Professor of Business Administration at HBS and Professor of Public Policy at the Harvard Kennedy School, brings deep expertise in the economics of health care markets and policy. We caught up with her to hear more about her background, research, and what excites her about joining HCI’s leadership team. [...]
At the intersection of engineering and advocacy, Jenn Arnold (MS/MBA’ 26) is helping lead a new wave of innovation in women’s health. With a background in mechanical and biomedical engineering and a passion for equity in health care, she’s leveraging her technical expertise to address long-overlooked challenges, especially those affecting women. We asked Jenn a few questions to learn more about her path, her perspective on AI, and why she believes women’s health is one of the most urgent and promising frontiers in health care today. [...]
Kasite Ugo-beke’s journey from Nigeria to Harvard Business School is a testament to the power of passion and purpose in healthcare innovation. From early experiences witnessing healthcare gaps to exploring the intersection of science and business, her time at HBS has reignited her drive to create meaningful, scalable impact. [...]
Recently the HCI was able catch up with this year's Health Care Club co-presidents Morgan Moncada and Hannah Truong as they reflect on their HBS experience, their thoughts on the current health care systems, and where they will be headed in the future.
In keeping with our mission to connect students, alumni and the greater health care community, we will continue to feature other members of the HCC throughout the upcoming school year to share their thoughts, experiences, and activities with us as well. [...]
Globally, there are about 350 million people, or 8% of the population, with a rare disease, yet only 5% of these diseases have an approved therapy. It’s a dilemma that is historically overlooked, largely because it’s hard to make a profit from a treatment that affects so few people. How do we empower patients with rare diseases when a lack of treatment options and awareness can result in significant health complications? [...]
Load More Loading...